Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2885 Ectopic Neuroendocrine Carcinoma: An Occult Source of ACTH

Introduction: About 250 cases of ectopic ACTH-producing neuroendocrine carcinoma (ACTH-NEC) have been reported; however metastatic ACTH-NEC of unknown primary is very rare. Usually are characterized by having a large cell, small cell, poorly differentiated or anaplastic cell, and Ki-67 index between 40-90%.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Huertas Gnecco B

Authors: Huertas Gnecco B, González Devia D, Alvaréz Figueroa J, Aguirre Matallana D, Cañón Solano D,

Keywords: Ectopic ACTH production, Cushing’s syndrome, Neuroendocrine carcinoma, Paraneoplastic Cushing syndrome, Ectopic Cushing´s syndrome,

#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: González Devia D

Authors: Guzman Ruiz Y, Vera Torres A, López Panqueva R, Ardila Duarte G, González Devia D,

Keywords: Pancreatic neuroendocrine tumors, Pancreatic tumor, Prognosis, Neuroendocrine tumor, Gastroenteropancreatic tumor,

#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice

Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Teulé A, Alonso T, González E, De La Cruz G, Houchard A,

Keywords: NET, lanreotide, pancreas, study,

#2122 Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?

Introduction: Quality of life (QoL) is important to all cancer patients. The EORTC QLQ-QNET21 is the most commonly used questionnaire in patients with neuroendocrine tumors (NETs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van Leeuwaarde R

Authors: Van Leeuwaarde R, Spada F, Cheung W, Gonzalez-Clavijo A, Pracht M,

Keywords: Quality of life, GEP-NET, EORTC QLQ-GINET21,

#1906 High Prevalence of the c.1546delC Germline Mutation in MEN1 Pancreatic Neuroendocrine Tumors

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease predisposing to pancreatic neuroendocrine neoplasms (NENs). Even though its genetics is relatively well known, specific phenotype-genotype correlations remain unproven at present. The Region of Murcia in southeast Spain is one of the areas with the highest incidence of MEN1

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marín Zafra G

Authors: Marín Zafra G, Carmona-Bayonas A, Segura Luque P, Rodríguez González J, Tebar Massó J,

Keywords: MEN1 genetics,